Cascadian Therapeutics Reaches Analyst Target Price
February 01, 2018 at 09:28 AM EST
In recent trading, shares of Cascadian Therapeutics Inc (CASC) have crossed above the average analyst 12-month target price of $8.50, changing hands for $10.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..